Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. (Nasdaq: NOVT) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a global supplier of core technology solutions for medical, life science, and advanced industrial OEMs. This SEC filings page brings together those disclosures so investors can review the company’s regulatory record in one place.
Among the most frequently referenced filings are current reports on Form 8-K, where Novanta announces quarterly financial results, provides non-GAAP metrics such as Adjusted EBITDA and Adjusted Diluted EPS, and discloses material events. Recent 8-K filings have covered results for specific fiscal quarters, revisions to financial guidance, changes in Board composition, and details of share repurchase authorizations.
Filings also document capital markets and financing transactions, including the underwriting agreement and terms of Novanta’s tangible equity units offering, which combines prepaid stock purchase contracts with senior amortizing notes due 2028. Related 8-Ks describe settlement mechanics, interest and installment payments, and the listing of the units under the symbol NOVTU. Other filings outline the terms of the company’s senior credit facilities under its Fourth Amended and Restated Credit Agreement and subsequent amendments, including leverage and coverage covenants.
Through this page, users can access Novanta’s 10-K annual reports and 10-Q quarterly reports (when filed), as well as Forms 4 and other ownership-related filings, via real-time updates from EDGAR. AI-powered summaries help explain complex sections, highlight key changes from prior periods, and clarify the implications of items such as guidance revisions, credit agreement provisions, and share repurchase programs.
Whether reviewing earnings-related disclosures, tracking capital structure developments, or examining governance and compensation information, this filings hub provides a structured entry point into Novanta’s SEC reporting history.
Novanta Inc. Co-Chief Operating Officer John Lesica reported multiple equity transactions on February 20, 2026. He received a grant of 7,537 Restricted Stock Units (RSUs), each representing one common share upon vesting. The RSUs vest in three equal installments on February 20, 2027, 2028, and 2029. He also exercised 1,633 RSUs into common stock and then had 480 common shares withheld at
Manganiello Alexander reported acquisition or exercise transactions in this Form 4 filing.
Novanta Inc. reported that its General Counsel, Alexander Manganiello, received a grant of 4,111 Restricted Stock Units on February 20, 2026. Each unit represents the right to receive one Novanta common share when it vests. The award vests in three equal installments on February 20, 2027, 2028, and 2029, providing long-term equity-based compensation that ties the executive’s interests to future company performance.
NOVANTA INC Chief Executive Officer Matthijs Glastra reported equity award activity involving performance stock units and common shares. On February 19, 2026, 7,825 Performance Stock Units were exercised, each converting into one common share, following Compensation Committee ratification based on 58.4% achievement of the performance target.
In connection with this vesting, 3,784 common shares were disposed of at $144.93 per share to satisfy tax obligations, a non‑open‑market, tax-withholding disposition. After these transactions, Glastra directly held 65,192 common shares, and an additional 54,382 common shares were held indirectly through the Matthijs Glastra 2021 Irrevocable Trust.
Novanta Inc Co-Chief Operating Officer Charles Guy Ravetto Jr reported equity award activity involving Performance Stock Units and common shares. On February 19, 2026, he exercised 722 Performance Stock Units at $0.00 per unit, converting them into 722 common shares.
The filing also shows a tax-withholding disposition of 251 common shares at a price of $144.93 per share, leaving him with 13,633 common shares held directly after these transactions. Footnotes state each Performance Stock Unit converts into one share and that the award size was set based on 58.4% achievement of a performance target.
NOVANTA INC Chief Financial Officer Robert Buckley exercised 2,935 Performance Stock Units into common shares, then used 1,420 shares to cover tax withholding at $144.93 per share. He now holds 92,549 shares directly and 36,219 shares indirectly through the Buckley Family Irrevocable Trust.
Novanta Inc. reports on its 2025 performance as a global supplier of precision technologies for medical and advanced industrial OEMs. For the year ended December 31, 2025, Automation Enabling Technologies generated revenue of $500.8 million with a gross profit margin of 47.8% and operating profit of $114.5 million, while Medical Solutions delivered revenue of $479.8 million with a 41.6% gross profit margin and operating profit of $51.2 million.
Medical end markets represented about 53% of revenue and advanced industrial about 47%. Backlog was approximately $481.2 million as of December 31, 2025. The company strengthened its balance sheet by issuing 12,650,000 6.50% tangible equity units at $50.00 per unit, recording net proceeds of $613.1 million, and by entering a new $1.0 billion credit facility maturing in June 2030. Novanta also acquired Keonn Technologies for a total purchase price of $75.1 million, expanding its RFID capabilities within the Medical Solutions segment. As of February 16, 2026, Novanta had 35,683,769 common shares outstanding and non‑affiliate market value of $3.50 billion based on June 27, 2025 pricing.
Novanta Inc. reported steady growth for the fourth quarter and full year 2025 while laying out an ambitious 2026 outlook. Fourth quarter 2025 revenue reached $258.3 million, up 8.5% year over year, with GAAP diluted EPS of $0.45 versus $0.46 and Adjusted diluted EPS rising 20% to $0.91. Adjusted EBITDA grew 17% to $60.7 million, supported by a 25% increase in customer bookings and a book-to-bill of 1.11x.
For full year 2025, revenue was $980.6 million, up 3.3%. GAAP diluted EPS declined to $1.47 from $1.77, but Adjusted diluted EPS improved 6.8% to $3.29 and Adjusted EBITDA increased to $221.0 million. Operating cash flow fell to $64.1 million from $158.5 million, mainly due to higher working capital from regionalizing manufacturing.
Novanta ended 2025 with $380.9 million of cash and $250.8 million of total debt, resulting in Net Debt of $(121.3) million. For 2026, the company guides GAAP revenue to $1,030–$1,050 million, Adjusted EBITDA to $245–$250 million and Adjusted diluted EPS to $3.50–$3.65, with operating cash flow of $145–$185 million, and expects mid‑single‑digit organic growth.
Novanta Inc. Co-Chief Operating Officer John Lesica reported equity award activity involving restricted stock units and common shares. He exercised or converted 1,388 restricted stock units into 1,388 common shares, then disposed of 445 common shares at $145.63 per share to cover tax obligations, leaving 943 common shares directly owned after these transactions. Each restricted stock unit represents one Novanta common share and vests in three equal installments on February 18, 2026, February 18, 2027 and February 18, 2028.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported an open‑market sale of 7,500 shares of common stock on February 10, 2026 at a weighted‑average price of $145.04 per share. The sale was made under a pre‑established Rule 10b5‑1 trading plan adopted on September 11, 2025.
Following this transaction, Glastra beneficially owns 57,367 Novanta shares directly and 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust, for which his spouse serves as trustee.
Novanta, Inc. has a new Rule 144 notice covering a planned sale of 7,500 shares of its common stock. The shares are to be sold through Merrill Private Wealth Management on NASDAQ, with an aggregate market value of 1087500 and 35775123 shares outstanding.
The shares to be sold were acquired as restricted stock units from Novanta, Inc. on 02/24/2022 (1084 shares), 01/03/2023 (4679 shares), and 01/02/2025 (1737 shares), all as equity compensation. A separate table shows that Matthijs Glastra has sold 323, 6177, 7500, and 6500 common shares in the past 3 months for gross proceeds of 41990, 803010, 1050000, and 877500.